What is the significance of elevated calprotectin levels in stool?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Significance of Elevated Fecal Calprotectin Levels

Elevated fecal calprotectin (>150 μg/g) indicates active intestinal inflammation and should prompt further evaluation for inflammatory bowel disease (IBD) or other inflammatory conditions through endoscopic assessment. 1, 2

Understanding Fecal Calprotectin

Fecal calprotectin is a calcium- and zinc-binding protein primarily derived from neutrophils that serves as a biomarker for intestinal inflammation. It has emerged as a valuable non-invasive tool to differentiate between inflammatory and non-inflammatory gastrointestinal conditions.

Interpretation of Calprotectin Levels

Level Interpretation Action
<50 μg/g Normal IBS likely, manage in primary care [1]
50-150 μg/g Borderline Consider repeat testing or routine referral [1,2]
>150 μg/g Elevated Refer for endoscopic assessment [1]
>250 μg/g Highly elevated Urgent referral to gastroenterology [1,2]

Clinical Significance of Elevated Levels

Elevated fecal calprotectin has several important clinical implications:

  • Differentiating IBD from IBS: Fecal calprotectin has high sensitivity (90.6%) for detecting endoscopically active disease at a cut-off of 50 μg/g and best specificity (78.2%) at levels >100 μg/g 1

  • Disease activity monitoring: In patients with known IBD, elevated levels correlate well with endoscopic inflammation in both ulcerative colitis and Crohn's disease 1

  • Predicting relapse: In patients with IBD in symptomatic remission but elevated biomarkers, repeat measurement in 3-6 months is recommended 1, 2

  • Treatment decisions: The American Gastroenterological Association (AGA) suggests using fecal calprotectin >150 mg/g to rule in active inflammation and inform treatment adjustments in patients with moderate to severe symptoms 1

Management Algorithm Based on Calprotectin Levels

For New Patients with GI Symptoms (Age 16-40):

  1. If calprotectin <100 μg/g:

    • IBS likely
    • Treat as IBS in primary care
    • Consider other differential diagnoses if symptoms persist 1
  2. If calprotectin 100-250 μg/g:

    • Consider repeat testing
    • Consider routine referral to gastroenterology 1
  3. If calprotectin >250 μg/g:

    • Refer urgently to gastroenterology
    • Exclude infectious causes before further investigation 1

For Known IBD Patients:

  1. If symptomatic with elevated calprotectin (>150 μg/g):

    • In moderate to severe symptoms: Use to confirm active inflammation and adjust treatment without routine endoscopy 1
    • In mild symptoms: Endoscopic assessment recommended before treatment adjustment 1
  2. If asymptomatic with elevated calprotectin:

    • Repeat measurement in 3-6 months
    • If persistently elevated, endoscopic assessment warranted 1, 2

Important Caveats and Pitfalls

  • False positives: Calprotectin may be elevated in:

    • Non-intestinal infections or inflammation
    • Colorectal cancer
    • Infectious gastroenteritis
    • NSAID use
    • Recent colonoscopy 1, 2
  • Sample collection: First morning stool is recommended; samples should be stored for no more than 3 days at room temperature 1

  • Age considerations: Calprotectin levels naturally increase with age 2

  • Test variability: Different commercial assays may have varying thresholds and performance characteristics 2

  • Not for cancer screening: Fecal calprotectin is not sensitive enough to exclude advanced colorectal adenoma or colorectal carcinoma 1

By understanding the significance of elevated fecal calprotectin and following appropriate management algorithms, clinicians can effectively utilize this biomarker to improve patient outcomes through early diagnosis, appropriate treatment, and monitoring of intestinal inflammatory conditions.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Gastrointestinal Inflammation Guideline

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.